SB 37 - AS INTRODUCED
2021 SESSION
21-0882
06/04
SENATE BILL 37
AN ACT relative to warning label requirements for marijuana products dispensed in
alternative treatment centers.
SPONSORS: Sen. Gannon, Dist 23; Sen. D'Allesandro, Dist 20; Sen. Ward, Dist 8; Rep. M.
Pearson, Rock. 34; Sen. Giuda, Dist 2; Sen. Prentiss, Dist 5; Rep. Weyler, Rock. 13
COMMITTEE: Commerce
─────────────────────────────────────────────────────────────────
ANALYSIS
This bill requires the department of health and human services to adopt rules that include
certain specific information on marijuana product labels dispensed in alternative treatment centers.
---------------------------------------------------------------------------
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
SB 37 - AS INTRODUCED
21-0882
06/04
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty One
AN ACT relative to warning label requirements for marijuana products dispensed in
alternative treatment centers.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 1 Findings. The general court recognizes that the side effects and risks of marijuana use on the
2 human body have advanced to a point that requires the department of health and human services to
3 update agency rules on packaging and labeling requirements for marijuana products dispensed in
4 alternative treatment centers. No detailed side effects or risks of use exist on current warning
5 labels.
6 2 Use of Cannabis for Therapeutic Purposes; Rules. Amend RSA 126-X:6, III(a)(9) to read as
7 follows:
8 (9) Labeling standards.
9 (A) Labels shall include a statement that the product has not been
10 analyzed or approved by the FDA, is not certified to be free of contaminants, that there is
11 limited detailed information on the side effects of using the product, and that there may be
12 serious associated health risks.
13 (B) Labels shall also state "Do not drive or operate heavy machinery
14 when under the influence of this product. KEEP THIS PRODUCT AWAY FROM
15 CHILDREN”; and
16 (C) Labels shall include side effects and use risks published by Centers
17 for Disease Control and Prevention, National Institute on Drug Abuse, the National
18 Academy of Sciences and the American Academy of Family Physicians. They shall include
19 but not be limited to: psychosis and schizophrenia, depression, anxiety, suicide, increased
20 blood pressure, increased respiratory rates, cardiac arrhythmia, heart failure, worsening
21 of glaucoma, cognitive impairment, addiction, allergic reactions, accidental poisoning and
22 coma in children, preterm births to pregnant women, and impacts on fetal brain
23 development.
24 3 New Paragraph; Use of Cannabis for Therapeutic Purposes; Duties. Amend RSA 132:2 by
25 inserting after paragraph XI the following new paragraph:
26 XII. Prepare, in conjunction with the bureau of alcohol and drug services and the division of
27 public health services, a brochure and a poster which provides information relative to the known
28 side effects and risks of marijuana use which shall be posted in a conspicuous location and available
29 to the public in all therapeutic cannabis dispensary locations pursuant to RSA 126-X:8.
30 4 Effective Date. This act shall take effect 60 days after its passage.
Statutes affected: Introduced: 126-X:6, 132:2
latest version: 126-X:6, 132:2